New Erbitux data = new chance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and ImClone "plan to discuss" the positive results of a Merck KGaA-sponsored study of Erbitux with FDA "as they relate to the U.S. filing for cetuximab in advanced colorectal cancer." FDA refused to file the BLA for the epidermal growth factor receptor antagonist in December 2001, and Bristol has projected a new BLA submission in 2004. Merck KGaA's Phase II study, presented at the American Society of Oncology annual meeting in Chicago June 1, compared cetuximab monotherapy and combination use with irinotecan in patients with irinotecan-refractory, EGFR-expressing colorectal cancer. Response rate was 22.9% for the combo vs. 10.8% for cetuximab-alone, median time to progression was 4.1 months vs. 1.5 months, overall rate of disease control was 55.5% vs. 32.4%, and median survival was 8.6 months vs. 6.9 months. The differences in response rate and time to progression were statistically significant, the companies report. Merck KGaA plans a mid-2003 European filing and a 2004 launch...
You may also be interested in...
Erbitux gets Swiss OK
Merck KGaA receives the first approval for colorectal cancer therapy Erbitux (cetuximab), with clearance in Switzerland Dec. 1 for use in combination with irinotecan. The application was submitted to Swissmedic and the EMEA at the end of June; EU marketing authorization is expected in mid-2004. Erbitux is pending at FDA with a mid-February user fee goal. Bristol/ImClone resubmitted the Erbitux NDA August 14 based on new data from a Merck KGaA study (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.